These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38696316)

  • 21. FGFR alterations in urothelial carcinoma: Picking the right target.
    Hubert P; Selmani Z; Loriot Y; Thiery-Vuillemin A
    Bull Cancer; 2021 Jun; 108(6):566-570. PubMed ID: 34020787
    [No Abstract]   [Full Text] [Related]  

  • 22. Toxicities of Novel Agents for the Treatment of Advanced Bladder Cancer.
    McInerney S; Jones RJ
    Eur Urol Focus; 2024 Mar; 10(2):222-223. PubMed ID: 38851928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erdafitinib exerts the anticancer effect on urothelial carcinoma
    Jin YY; Tong SQ; Tong M
    Pharmazie; 2020 May; 75(5):195-197. PubMed ID: 32393427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
    Loriot Y; O'Hagan A; Siefker-Radtke AO
    Future Oncol; 2024 Feb; 20(5):231-243. PubMed ID: 37916514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
    Nishina T; Takahashi S; Iwasawa R; Noguchi H; Aoki M; Doi T
    Invest New Drugs; 2018 Jun; 36(3):424-434. PubMed ID: 28965185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
    Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
    J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
    Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
    Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast growth factor receptor (
    Al-Obaidy KI; Cheng L
    J Clin Pathol; 2021 Aug; 74(8):491-495. PubMed ID: 33731335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
    Rexer H; Ohlmann CH; Gschwend J;
    Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
    [No Abstract]   [Full Text] [Related]  

  • 30. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    Loriot Y; Matsubara N; Park SH; Huddart RA; Burgess EF; Houede N; Banek S; Guadalupi V; Ku JH; Valderrama BP; Tran B; Triantos S; Kean Y; Akapame S; Deprince K; Mukhopadhyay S; Stone NL; Siefker-Radtke AO;
    N Engl J Med; 2023 Nov; 389(21):1961-1971. PubMed ID: 37870920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a role for pembrolizumab beyond progression in urothelial carcinoma?
    Taguchi S; Kawai T; Nakagawa T; Kume H
    BJU Int; 2024 Jul; 134(1):43-44. PubMed ID: 38073020
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Goto Y
    Int J Urol; 2023 Sep; 30(9):704. PubMed ID: 36482811
    [No Abstract]   [Full Text] [Related]  

  • 33. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
    de Almeida Carvalho LM; de Oliveira Sapori Avelar S; Haslam A; Gill J; Prasad V
    JAMA Netw Open; 2019 Nov; 2(11):e1916091. PubMed ID: 31755953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The future of drug development in urothelial cancer.
    Dreicer R
    J Clin Oncol; 2012 Feb; 30(5):473-5. PubMed ID: 22184400
    [No Abstract]   [Full Text] [Related]  

  • 35. [Not Available].
    Aktuelle Urol; 2024 Aug; 55(4):297-298. PubMed ID: 39047749
    [No Abstract]   [Full Text] [Related]  

  • 36. Case Report: Erdafitinib-induced Central Serous Chorioretinopathy.
    Claiborne RT; Tsan GL
    Optom Vis Sci; 2022 Jan; 99(1):88-92. PubMed ID: 34882600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zschäbitz S; Niegisch G
    Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
    Qin Q; Patel V; Galsky MD
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.
    Niegisch G
    N Engl J Med; 2024 Mar; 390(10):944-946. PubMed ID: 38446680
    [No Abstract]   [Full Text] [Related]  

  • 40. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
    Weaver A; Bossaer JB
    J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.